Evain-Brion D, Garnier P, Blanco-Garcia M, Job J C
J Clin Endocrinol Metab. 1984 Jun;58(6):1022-6. doi: 10.1210/jcem-58-6-1022.
After previous demonstration of paradoxical GH responses to TRH and oral glucose loading tests in some constitutionally tall adolescents, we studied the effects of a small dose of bromocriptine (5 mg/day) on GH secretion and adult height prediction. In 10 patients, each of whom had a substantial plasma GH increase after TRH injection, bromocriptine reduced or suppressed this abnormal response. In 4 of these patients who also had paradoxical GH increases after glucose loading, bromocriptine suppressed this abnormality in 2. Predicted adult height was reduced in 10 of the 12 patients after 6-12 months of treatment. This reduction resulted either from a decrease in growth velocity, an increase in skeletal maturation rate, or both. Since no side effects were noticed we suggest that bromocriptine may be a valuable alternative to sex steroid treatment to limit final height in excessively tall adolescents.
在先前证明一些体质性身材高大的青少年对促甲状腺激素释放激素（TRH）和口服葡萄糖负荷试验存在矛盾的生长激素（GH）反应后，我们研究了小剂量溴隐亭（5毫克/天）对GH分泌及成人身高预测的影响。在10名患者中，每例在注射TRH后血浆GH均有显著升高，溴隐亭使这种异常反应减弱或受到抑制。在这10名患者中有4名在葡萄糖负荷后也出现矛盾的GH升高，溴隐亭使其中2例的这种异常得到抑制。治疗6 - 12个月后，12例患者中有10例预测成人身高降低。这种降低要么是由于生长速度减慢，要么是骨骼成熟速率加快，或者两者皆有。由于未观察到副作用，我们认为溴隐亭可能是性类固醇治疗的一种有价值的替代方法，用于限制身材过高青少年的最终身高。
